Quantcast
Channel: Australia Headlines on One News Page [United Kingdom]
Viewing all 51987 articles
Browse latest View live
↧

VOD INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Vodafone Group Public Limited Company and a Lead Plaintiff Deadline of March 20, 2018

March 5, 2018, 12:44 pm
$
0
0
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Vodafone Group Public Limited Company ("Vodafone") (NASDAQ:VOD) ADRs between February 11, 2015 and January 11, 2018.Click here to learn about the case: http://www.wongesq.com/pslra-sbm/vodafone-group-public-limited-company?wire=2. There is no cost or obligation to you.

According to the complaint, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that Vodafone had contravened Australian law by permitting customers to purchase pre-paid mobile phones without first verifying their identities.

On January 10, 2018, the Australian Communications and Media Authority (“ACMA”) issued a press release disclosing that, following an investigation into Vodafone Australia, it determined that the Company had “failed to verify the identity of at least 1,028 customers before activating their prepaid mobile services.” Upon this news, Vodafone ADRs declined from a closing price of $32.60 on January 9, 2018, to a closing price of $31.44 on January 11, 2018.

If you suffered a loss in Vodafone you have until *March 20, 2018* to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/vodafone-group-public-limited-company?wire=2.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com  Reported by GlobeNewswire 24 minutes ago.
↧
Search

Olympus Stem Cells Pty Ltd: Olympus Stem Cells Achieving 100% Stem Cell Viability Confirmed with Muse Analyzer Testing

March 12, 2018, 10:26 am
$
0
0
SYDNEY, AUSTRALIA / ACCESSWIRE / March 12, 2018 / Medical clinic and research facility Olympus Stem Cells Pty Ltd, based in Sydney Olympic Park, NSW, Australia, are pleased to announce the validati... Reported by FinanzNachrichten.de 5 hours ago.
↧
↧

University graduates are more outgoing and agreeable

March 12, 2018, 11:11 am
$
0
0
University graduates are more outgoing and agreeable Researchers from Monash University in Australia followed 575 Australian adolescents as they went from teenagers to adults. Those that went to university were more agreeable, and outgoing. Reported by MailOnline 4 hours ago.
↧

How an Australian bank laundered money for Hong Kong drug gangs

March 12, 2018, 10:51 am
$
0
0
The Commonwealth Bank of Australia allowed cash deposits without legal safeguards Reported by FT.com 5 hours ago.
↧

JAGGAER & Kloepfel iProcurement Partnership Enhances Strategic Sourcing Solution with AI Technology

March 12, 2018, 11:11 am
$
0
0
VIENNA, Austria and RESEARCH TRIANGLE PARK, N.C., March 12, 2018 (GLOBE NEWSWIRE) -- JAGGAER, the world’s largest independent spend management company, has expanded its partnership with Kloepfel iProcurement, part of Kloepfel Group, to amplify both the data analysis capabilities of the JAGGAER Direct strategic sourcing solution, and the data collection process of the iProcurement tool. Holistic digitalization consultants and solutions provider Kloepfel Group operates across 13 global locations, offering technology, coaching, and seminars to support the procurement function. By incorporating iProcurement’s artificial intelligence technology for generating cost-reduction recommendations, JAGGAER’s Direct strategic sourcing platform will enable customers to make better decisions faster while saving more on costs and resources.

“With iProcurement, we’re giving our customers a user-friendly tool that can be implemented quickly and presents consolidated figures. By adding external data with the help of the JAGGAER solution, customers can gain enhanced and more valuable insights from their own data,” said Christopher Messina, CEO at Kloepfel iProcurement.

Both companies have made it a priority to learn from each other and work together to meet their customer’s requirements. The combined technology is easy to use and can easily be connected to customer’s systems, ensuring quick set up and immediate functionality. With this partnership, every JAGGAER Direct customer will receive a free iProcurement license for data analysis. JAGGAER customers can also purchase iProcurement licenses directly from JAGGAER. Companies that are already working with the JAGGAER Direct strategic sourcing solution will be able to benefit from the reporting and forecasting models generated by the innovative and intelligent algorithm-based iProcurement tool. Both the JAGGAER solution and Kloepfel iProcurement can be expanded with additional modules, offering companies a flexible solution for structuring transparent purchasing negotiations, achieving better supplier conditions, and monitoring savings potential at the supplier and item level in real-time.

“The JAGGAER Direct strategic sourcing platform eliminates the manual aspects of the sourcing process and delivers a 360° view of transparent price and non-price information. In combination with Kloepfel iProcurement, customers can leverage the new AI technology for enhanced data analysis to make the best strategic decisions,” said Robert Bonavito, CEO at JAGGAER.

*About Kloepfel iProcurement *
As part of the international Kloepfel Group, Kloepfel iProcurement digitalizes the entire chain of procurement processes with practical and intuitive standardized solutions. As holistic digitalization consultants and solution providers, they also offer technology, coaching, and seminars to support the procurement function. Kloepfel iProcurement sees its relationship with customers as a partnership where both sides work together to create new digital ways forward. With their core competencies in business analytics and business intelligence, they work with you to structure optimal procurement processes.  As part of this process, they create innovative procurement and controlling solutions that will guide your digital transformation and increase efficiency and transparency in your organization.

*ABOUT JAGGAER: GLOBAL INDIRECT AND DIRECT SPEND MANAGEMENT SOLUTIONS*
JAGGAER is the world’s largest independent spend management company, with over 1,850 customers connected to a network of 3.7 million suppliers in 70 countries, served by offices located in North America, Latin America, throughout Europe, the United Kingdom, Australia, Asia, and the Middle East. JAGGAER offers complete SaaS based indirect and direct eProcurement solutions with advanced spend analytics, complex sourcing, supplier management, contract lifecycle management, savings tracking, and intelligent workflow capabilities. We have pioneered spend solutions for over two decades and continue to lead the innovation curve by listening to customers and analyzing the market. Our solutions suites are trusted by the world’s largest education, manufacturing, health care, retail, consumer package goods, logistics, construction, utilities companies and public service organizations. Additionally, JAGGAER holds 38 patents–more than any other spend management company. www.JAGGAER.com.

To join the conversation, please visit our blog at www.JAGGAER.com/blog/ or follow us on Twitter @JAGGAERPro.

*MEDIA CONTACT*
news@JAGGAER.com
919-659-NEWS Reported by GlobeNewswire 4 hours ago.
↧
↧

Stratfor Forecasts Global Trade Offensive and Retaliation to Shape Key Geopolitical Trends in Second Quarter of 2018

March 12, 2018, 11:11 am
$
0
0
AUSTIN, Texas, March 12, 2018 (GLOBE NEWSWIRE) -- Stratfor, the world’s leading geopolitical intelligence platform, forecasts a U.S.-led global trade offensive, retaliation and associated repercussions to primarily shape international affairs in the second quarter of 2018. Stratfor’s 2018 Second-Quarter Forecast, designed to help companies, governments and globally engaged individuals stay focused on strategic plans while identifying key geopolitical risks and opportunities, builds upon Stratfor’s 2018 Annual Forecast released at the beginning of the year.“The White House is ready to take aim at the global economy this quarter and the bull’s-eye is sitting squarely on Beijing,” said Stratfor Vice President of Global Analysis Reva Goujon, noting that many nations, to include some U.S. allies, will retaliate by targeting politically sensitive sectors. “In addition to imposing its own restrictions on some U.S. agricultural goods, Beijing is likely to selectively apply regulatory pressure on American companies with stakes in China.”

Stratfor’s forecast for the second quarter identifies the key geopolitical trends that will fundamentally shape and constrain the actions of both nations and industries in the months ahead. Updated with strategic analysis and other guidance throughout the year on Stratfor Worldview, the forecasts helps individual, team and enterprise members cut through daily information noise and focus on what’s truly significant versus merely important.

Additional developments Stratfor forecasts for the second quarter include:

· Tension between the United States and China will spike, putting businesses caught in the fray at risk.
· The development of disruptive weapons technology among the United States, China and Russia will further degrade the world’s arms control treaties.
· Building upon a brief détente, South Korea will try to persuade the United States and North Korea to reconcile their positions on denuclearization.
· Debate over eurozone reforms will expose the deeper divides threatening European unity.
· Trade tensions will mar Washington’s rocky relationship with Brazil over how to manage Venezuela’s economic crisis.
· China’s wide maritime reach will draw India into closer defense cooperation with the United States, Japan and Australia.
· Turkey will push its troops deeper into northern Syria and Iraq while laying claim to the eastern Mediterranean Sea.

The complete 2018 Second-Quarter Forecast is now available on Stratfor Worldview. Accurate calls from the 2018 Annual Forecast thus far include: the Trump administration launching its protectionist trade agenda, Chinese President Xi Jinping moving to maintain his unrivaled authority, India teaming up with China’s regional rivals, Saudi Crown Prince Mohammed bin Salman making good on his promise of aggressive economic reform, and South African President Jacob Zuma’s resignation.

*About Stratfor*
As the world's leading geopolitical intelligence platform, Stratfor brings valuable context to global events, empowering businesses, governments and individuals to more confidently navigate their way through an increasingly complex international environment. By leveraging a deep understanding of history, politics and geography in conjunction with our unique methodology, Stratfor delivers informed perspectives on today's events and develops a more accurate view of the future. Information about individual, team and enterprise membership is available at Stratfor.com.

*For more information, contact*:
Joshua Cook
Stratfor Director of Public Relations
pr@stratfor.com
512.744.4309 Reported by GlobeNewswire 4 hours ago.
↧

Golf-Els to captain Internationals at 2019 Presidents Cup

March 12, 2018, 12:19 pm
$
0
0
March 12 (Reuters) - South African Ernie Els will be captain of the International team for next year's Presidents Cup at Royal Melbourne Golf Club in Australia, a source told Reuters on Monday. Reported by Reuters India 3 hours ago.
↧

Asia and Australia Edition: Russia, Kathmandu, Hubert de Givenchy: Your Tuesday Briefing

March 12, 2018, 12:15 pm
$
0
0
Here’s what you need to know to start your day. Reported by NYTimes.com 3 hours ago.
↧
Search

Navigant Expands into Australia

March 12, 2018, 12:05 pm
$
0
0
Navigant Expands into Australia CHICAGO & PERTH, Australia--(BUSINESS WIRE)--Navigant (NYSE: NCI) today announced the expansion of its global Construction practice (GCP) into Australia, with new offices in Perth and Sydney. The expansion of Navigant’s global Construction practice, a practice within the company’s Disputes, Forensics, and Legal Technology (DFLT) segment, is another step in expanding Navigant’s global, industry-leading expert and advisory services work for high-stakes legal and regulatory proceedings. “Our forma Reported by Business Wire 3 hours ago.
↧
↧

Golf: Els to captain Internationals at 2019 Presidents Cup

March 12, 2018, 12:27 pm
$
0
0
(Reuters) - South African Ernie Els will be captain of the International team for next year's Presidents Cup at Royal Melbourne Golf Club in Australia, a source told Reuters on Monday. Reported by Reuters 3 hours ago.
↧

Cricket-S.Africa will look to stalwarts to replace Rabada in third test

March 12, 2018, 1:33 pm
$
0
0
CAPE TOWN, March 12 (Reuters) - The fitness of experienced fast bowler Dale Steyn will be of even more interest to South Africa in the coming days after their most potent wicket-taker Kagiso Rabada was ruled out of the remainder of the four-test series with Australia. Reported by Reuters India 2 hours ago.
↧

Why Japanese steak house Ikinari is growing so fast in New York City

March 12, 2018, 12:57 pm
$
0
0
When most restaurant chains expand in New York City, they proceed slowly and cautiously. High rents and intense competition drive their prudent approach.   But not Ikinari Steak, a Japan-based steak chain with 188 restaurants, mostly in Japan with some in Australia. It is going full steam ahead in its New York expansion, with plans to add 11 outposts in Manhattan by the end of 2018. So far it has opened five. In fact, it’s hard to pass a corner in Manhattan these days without seeing a sign… Reported by bizjournals 2 hours ago.
↧

Come on in! Australia's secret to avoiding recessions

March 12, 2018, 1:53 pm
$
0
0
The Turnbull government is standing firm amid growing calls for immigration cuts. It has little choice if it's to continue its era of record economic expansion. Reported by Brisbane Times 2 hours ago.
↧
↧

Usain Bolt Has a Line of Hot Sauces Available in Australia

March 12, 2018, 1:27 pm
$
0
0
Usain Bolt Has a Line of Hot Sauces Available in Australia Three are three flavors of Usain's Insane Hot Sauces available to buy. Reported by SI.com 2 hours ago.
↧

Sport24.co.za | Steyn ruled out of Newlands Test

March 12, 2018, 1:29 pm
$
0
0
The Proteas' selectors face a daunting task assembling a bowling attack for the third Test against Australia at Newlands in Cape Town. Reported by News24 2 hours ago.
↧
Search

Isagenix Matches Jon Rahm’s $21,000 Donation to the Mexican Red Cross

March 12, 2018, 1:32 pm
$
0
0
Isagenix International is matching PGA Tour star Jon Rahm’s $21,000 donation to the Mexican Red Cross to help those affected by the recent earthquakes in Mexico.

GILBERT, Ariz. (PRWEB) March 12, 2018

Isagenix International, a global health and wellness company providing nutrition and lifestyle solutions, is pleased to announce it is matching PGA Tour star Jon Rahm’s $21,000 donation to the Mexican Red Cross. The donation stems from the Team Isagenix Elite athlete’s performance at the WGC-Mexico Championship March 1-4. Shortly before the golf tournament, Rahm, ranked No. 2 in the world, announced he would contribute $1,000 for every birdie and $3,000 for every eagle to the Mexican Red Cross to help those affected by the recent earthquakes in Mexico.

“As soon as we heard what Jon was doing, we had to get involved,” said Erik Coover, Isagenix senior vice president of global field development and culture. “Isagenix is passionate about helping victims of disaster, so Jon’s generosity and heart for the people of Mexico really resonated with us. We’re honored to help him support the Mexican Red Cross as it provides much-needed assistance to those affected by the earthquakes.”

The company’s matching donation marks the second time Isagenix has contributed to the Mexican Red Cross. In 2017, it donated to the organization’s earthquake disaster fund. Isagenix also encouraged its customers to purchase a box of IsaBar™ Avena con Pasas protein meal replacement bars last year to donate to Mexican Red Cross relief efforts. The company matched those purchases by donating one box of IsaBar for each box purchased.

In 2017, Isagenix contributed nearly $7 million in monetary and product donations to disaster relief and charitable groups supporting children and families.

“I’m thrilled that Isagenix is matching my donation so it will have the greatest impact possible on a community that needs our help,” Rahm said. “I truly appreciate having a sponsor that supports and shares my desire to make a difference in the lives of others.”    

To learn more about Isagenix, visit our newsroom at Isagenix.com, like us on Facebook at Facebook.com/Isagenix, and follow us on Twitter and Instagram at @Isagenix.

About Isagenix International
Established in 2002, Isagenix provides systems for weight wellness, energy, performance, healthy aging, and wealth creation. With nearly 600,000 customers worldwide and more than 100 life-changing products, packs, and systems globally, the company is committed to producing Solutions to Transform Lives™. Since its inception in 2002, Isagenix has generated nearly $6 billion in cumulative global sales through an independent network of associates in the U.S., Canada, Puerto Rico, Hong Kong, Australia, New Zealand, Taiwan, Mexico, Singapore, Malaysia, Colombia, Indonesia, the United Kingdom, Ireland, and the Netherlands. Isagenix is a privately owned company with headquarters in Gilbert, Arizona. For more information, visit Isagenix.com. Reported by PRWeb 2 hours ago.
↧

Precision Therapeutics Appoints Kevin Hungerford as Vice President of Sales and Marketing

March 12, 2018, 1:41 pm
$
0
0
MINNEAPOLIS, March 12, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that it has appointed Kevin Hungerford as Global Vice President of Sales and Marketing, effective immediately. Based in the United States, Mr. Hungerford will be responsible for overseeing all sales and marketing activities for the Company’s FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal to hospitals and medical centers. He will report to Dr. Carl Schwartz, Chief Executive Officer, and replaces Mr. Peter Alex, who is stepping down to pursue other opportunities.This new appointment follows the launch of the Company’s aggressive new U.S. sales and marketing campaign for the STREAMWAY system, which resulted in a meaningful ramp in domestic sales in the fourth quarter of 2017 and early 2018. The Company has also made initial investments in its international sales and marketing strategy by signing independent distribution agreements in Australia, Canada and Switzerland, as announced in November 2017, opening a European Headquarters in Brussels, Belgium, and appointing a Vice President of International Sales, Mr. Jean-Paul Rasschaert.

Mr. Hungerford is a senior executive with over 20 years of sales and marketing experience in the U.S. medical device market. He joins Precision Therapeutics from Sirtex Medical, a global medical device company, where he worked from 2012 – 2018 in a variety of positions of increasing seniority, most recently as the Director of Marketing where he was responsible for overseeing all Interventional Radiology (IR) marketing activities and professional education. He previously worked at Boston Scientific Endoscopy from 1997 – 2012 where he led several sales teams who were directed to drive market-share, new technology and market adoption of key technologies.

Dr. Carl Schwartz, Chief Executive Officer at Precision Therapeutics, commented, “Kevin has extensive sales experience in the medical device market, most recently in the Interventional Radiology space, which is one of the STREAMWAY’s core markets. His background at reputable, global companies, such as Sirtex Medical and Boston Scientific Endoscopy, and vast network of healthcare contacts, are expected to boost our reputation as a best-in-class provider of fluid management systems and allow us to broaden our market reach. Kevin will oversee our aggressive new sales and marketing strategy, launched in 2017, which includes several international distribution agreements and the opening of our new European Headquarters in Belgium. I would like to thank Peter Alex for his commitment and contributions to the Company and the work he has done to position it for near and long-term sales growth.”

Mr. Kevin Hungerford, Vice President of Sales and Marketing for Precision Therapeutics’ Skyline Medical division, commented, “The STREAMWAY is a unique solution for medical waste management that virtually eliminates staff exposure to potentially infectious fluids found in the healthcare environment. From my years interacting with the healthcare community it is evident to me that it has the potential to revolutionize our approach to health and safety in the operating room and fulfils an unmet need in the market. I am pleased to join the Company and look forward to driving sales and building value for the Company.”

As part of Mr. Hungerford’s compensation package, he will receive inducement stock options in accordance with NASDAQ listing rules for 111,112 shares of Precision Therapeutics common stock at $1.35 per share. The options will vest quarterly in four equal installments over a 12-month period and have a term of 10 years. The options are subject to the terms and conditions detailed in the Company’s stock incentive plan.

*About the STREAMWAY System*

Produced by Skyline Medical, a division of Precision Therapeutics, the revolutionary, FDA-cleared STREAMWAY System is the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a facility's plumbing system to automate the collection, measurement and disposal of waste fluids. 

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater profitability. Furthermore, the STREAMWAY eliminates canisters to reduce overhead costs and provides greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the U.S.  For a demonstration please visit www.skylinemedical.com or call 855-785-8855.

*About Precision Therapeutics Inc.*

Precision Therapeutics (NASDAQ:AIPT) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal.

Precision Therapeutics' CRO services business is committed to improving the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to rich data diseases databases. This business has launched with Precision Therapeutics' investment in Helomics Corporation, a precision diagnostic company and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace.  In addition to its proprietary precision diagnostics for oncology, Helomics offers boutique CRO services that leverage our patient-derived tumor models, coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to our client's specific needs. Helomics is 25% owned by Precision Therapeutics.  Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information, please visit www.Helomics.com. Precision Therapeutics and Helomics have also announced a proposed joint venture with GLG Pharma focused on using their combined technologies to bring personalized medicines and testing to ovarian and breast cancer patients, especially those who present with ascites fluid (over one-third of patients). The growth strategy in this business includes securing new partnerships and considering acquisitions in the precision medicine space.

Sold through the Skyline Medical business of Precision Therapeutics, The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S.  For additional information, please visit www.skylinemedical.com.

*Forward-looking Statements*

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to the proposed joint ventures, including the need to negotiate the definitive agreements for the joint ventures; possible failure to realize anticipated benefits of the joint ventures; and costs of providing funding to the joint ventures. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues;  sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov.  This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.

*Contacts:*
Investor Relations
KCSA Strategic Communications
Elizabeth Barker
(212) 896-1203
ebarker@kcsa.com

MONEYINFO, LLC
Charles Moskowitz
617-827-1296
info@moneyinfo-llc.com 

  Reported by GlobeNewswire 2 hours ago.
↧
↧

The Latest Challenger To Lithium-Ion Batteries

March 12, 2018, 2:11 pm
$
0
0
The race for cheaper, better batteries has never been more intense and more interesting. The latest contender comes from Australia, from RMIT University. It is a hybrid between a chemical battery and a fuel cell that combines cheap resources—carbon and water—and promising efficiency. The battery works by breaking down water in the fuel cell with the help of electrons from an electric circuit. The protons resulting from this breakdown pass the cell membrane and bond with the carbon electrode where they are stored as hydrogen ions. That’s… Reported by OilPrice.com 1 hour ago.
↧

MD for Men Announces Dr. Wayne Kuang's Designation as a UroLift® Center of Excellence

March 12, 2018, 2:04 pm
$
0
0
Designation Recognizes Dr. Wayne Kuang's Commitment to Exemplary Care, Deep UroLift Experience

ALBUQUERQUE, N.M. (PRWEB) March 12, 2018

MD for Men specializing in Hotel Healthcare Hospitality today announces that Dr. Wayne Kuang has been designated as the first UroLift® Center of Excellence in New Mexico. The designation recognizes that Dr. Kuang has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH.

"The UroLift System is a breakthrough minimally invasive treatment that typically takes less than an hour and can offer multiple benefits for men with enlarged prostate - no cutting, heating, or removal of tissue, minimal downtime, no compromise of sexual function, and no need for continued medications," said Dr. Kuang. "I am proud to be a national leader offering this breakthrough treatment option."

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

About the UroLift System
NeoTract's FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About MD for Men
A men's health center empowering men with the guest experience to evolve fearlessly into the best version of themselves to positively impact their personal, professional, community and global relationships. Specializing in Vasectomy, Enlarged Prostate, Testosterone Balancing & Sexual Health. Learn more at http://www.mdformen.com

# # #

Media Contact:
Amy Cramer
M: 650-391-3714
Amy(at)healthandcommerce(dot)com Reported by PRWeb 1 hour ago.
↧

Delivery Hero AG: Placement price for new shares issued in connection with existing stock option program and sold for option holders has been set

March 12, 2018, 2:20 pm
$
0
0
DGAP-News: Delivery Hero AG / Key word(s): Capital Increase

12.03.2018 / 22:12
The issuer is solely responsible for the content of this announcement.
--------------------

*Delivery Hero AG: Placement price for new shares issued in connection with existing stock option program and sold for option holders has been set*

*Berlin, March 12, 2018* - As announced today, the management board of Delivery Hero AG ("Delivery Hero"), with the consent of the supervisory board, resolved to issue new shares under exclusion of shareholders' subscription rights with regard to the existing stock option program for current and former employees, directors and supporters of Delivery Hero and its subsidiaries. 1,366,311 new ordinary registered shares ("New Shares"), representing approx. 0.75% of Delivery Hero's share capital, will be issued to beneficiaries of the stock option program who have exercised their stock options. Delivery Hero's share capital will be increased by an amount of EUR 1,366,311 from EUR 182,498,900 to EUR 183,865,211.

1,263,111 of these New Shares have been placed with institutional investors through an accelerated bookbuilt offering upon direction and for the benefit of certain beneficiaries, mainly former employees, directors and supporters, inter alia, so that they can finance the exercise prices and income taxes. The placement price for the New Shares was set at EUR 38,50. UniCredit Bank AG acted as Sole Bookrunner on the share placement.

 

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation to buy any securities. The securities have already been sold.

This publication may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction where such announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this document or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of Delivery Hero AG or of any of its subsidiaries in the United States of America, Germany or any other jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The securities referred to herein may not be offered or sold in the United States of America in the absence of registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the 'Securities Act'). The securities of Delivery Hero AG have not been, and will not be, registered under the Securities Act.

In the United Kingdom, this announcement is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the 'Order') or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as 'Relevant Persons'). This document must not be acted on, or relied upon, by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In member states of the European Economic Area which have implemented Directive 2003/71/EC and any amendments thereto, in particular, Directive 2010/73/EU, this announcement and any offer, if made subsequently, is directed exclusively at persons who are 'qualified investors' within the meaning of the Prospectus Directive.

No action has been taken that would permit an offering or acquisition of the securities or a distribution of this announcement in any jurisdiction where such action would be unlawful. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

This release may contain forward looking statements, estimates, opinions and projections with respect to anticipated future performance of Delivery Hero AG ("forward-looking statements"). These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes,""estimates,""anticipates,""expects,""intends,""may,""will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of Delivery Hero AG and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release. We undertake no obligation, and do not expect to publicly update, or publicly revise, any of the information, forward-looking statements or the conclusions contained herein or to reflect new events or circumstances or to correct any inaccuracies which may become apparent subsequent to the date hereof, whether as a result of new information, future events or otherwise. We accept no liability whatsoever in respect of the achievement of such forward-looking statements and assumptions.

In connection with the transaction described above (the 'Placement'), UniCredit Bank AG is acting exclusively for Delivery Hero AG. It will not regard any other person as its clients in relation to the transaction and will neither be responsible nor provide protection to anyone other than Delivery Hero AG, nor will it provide advice to anyone other than Delivery Hero AG in relation to the Placement, the contents of this announcement or any other matter referred to herein.

In connection with the Placement, UniCredit Bank AG and any of its affiliates, acting as investors for their own accounts, may subscribe for or purchase securities of Delivery Hero AG and may otherwise deal for their own accounts. Accordingly, references to the securities issued or sold should be read as including any issue, offer or sale to UniCredit Bank AG and any of its affiliates acting as investors for their own accounts. In addition UniCredit Bank AG or its affiliates may enter into financing arrangements and swaps with investors in connection with which UniCredit Bank AG (or its affiliates) may from time to time acquire, hold or dispose of Delivery Hero AG's shares. UniCredit Bank AG does not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

Neither UniCredit Bank AG nor any of its directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or, with limited exception, other information relating to Delivery Hero AG, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

Contact:
Bodo v. Braunmühl
Head of Corporate Communications --------------------

12.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: Delivery Hero AG
Oranienburger Straße 70
10117 Berlin
Germany
Phone: +49 (0)30 5444 59 000
Fax: +49 (0)30 5444 59 024
E-mail: info@deliveryhero.com
Internet: www.deliveryhero.com
ISIN: DE000A2E4K43
WKN: A2E4K4
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
 
End of News DGAP News Service Reported by EQS Group 1 hour ago.
↧
Viewing all 51987 articles
Browse latest View live
Search
<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>